Cargando…
Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain
BACKGROUND: In patients with HIV/AIDS receiving antiretroviral therapy (ART), HIV-1 persistence in brain tissue is a vital and unanswered question. HIV-1 infects and replicates in resident microglia and trafficking macrophages within the brain although the impact of individual ART drugs on viral inf...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644262/ https://www.ncbi.nlm.nih.gov/pubmed/29037245 http://dx.doi.org/10.1186/s12977-017-0370-5 |
_version_ | 1783271702532194304 |
---|---|
author | Asahchop, Eugene L. Meziane, Oussama Mamik, Manmeet K. Chan, Wing F. Branton, William G. Resch, Lothar Gill, M. John Haddad, Elie Guimond, Jean V. Wainberg, Mark A. Baker, Glen B. Cohen, Eric A. Power, Christopher |
author_facet | Asahchop, Eugene L. Meziane, Oussama Mamik, Manmeet K. Chan, Wing F. Branton, William G. Resch, Lothar Gill, M. John Haddad, Elie Guimond, Jean V. Wainberg, Mark A. Baker, Glen B. Cohen, Eric A. Power, Christopher |
author_sort | Asahchop, Eugene L. |
collection | PubMed |
description | BACKGROUND: In patients with HIV/AIDS receiving antiretroviral therapy (ART), HIV-1 persistence in brain tissue is a vital and unanswered question. HIV-1 infects and replicates in resident microglia and trafficking macrophages within the brain although the impact of individual ART drugs on viral infection within these brain myeloid cells is unknown. Herein, the effects of contemporary ART drugs were investigated using in vitro and in vivo models of HIV-1 brain infection. RESULTS: The EC(50) values for specific ART drugs in HIV-infected human microglia were significantly higher compared to bone marrow-derived macrophages and peripheral blood mononuclear cells. Intracellular ART drug concentrations in microglia were significantly lower than in human lymphocytes. In vivo brain concentrations of ART drugs in mice were 10 to 100-fold less in brain tissues compared with plasma and liver levels. In brain tissues from untreated HIV-infected BLT mice, HIV-encoded RNA, DNA and p24 were present in human leukocytes while ART eradicated viral RNA and DNA in both brain and plasma. Interruption of ART resulted in detectable viral RNA and DNA and increased human CD68 expression in brains of HIV-infected BLT mice. In aviremic HIV/AIDS patients receiving effective ART, brain tissues that were collected within hours of last ART dosing showed HIV-encoded RNA and DNA with associated neuroinflammatory responses. CONCLUSIONS: ART drugs show variable concentrations and efficacies in brain myeloid cells and tissues in drug-specific manner. Despite low drug concentrations in brain, experimental ART suppressed HIV-1 infection in brain although HIV/AIDS patients receiving effective ART had detectable HIV-1 in brain. These findings suggest that viral suppression in brain is feasible but new approaches to enhancing ART efficacy and concentrations in brain are required for sustained HIV-1 eradication from brain. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12977-017-0370-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5644262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56442622017-10-26 Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain Asahchop, Eugene L. Meziane, Oussama Mamik, Manmeet K. Chan, Wing F. Branton, William G. Resch, Lothar Gill, M. John Haddad, Elie Guimond, Jean V. Wainberg, Mark A. Baker, Glen B. Cohen, Eric A. Power, Christopher Retrovirology Research BACKGROUND: In patients with HIV/AIDS receiving antiretroviral therapy (ART), HIV-1 persistence in brain tissue is a vital and unanswered question. HIV-1 infects and replicates in resident microglia and trafficking macrophages within the brain although the impact of individual ART drugs on viral infection within these brain myeloid cells is unknown. Herein, the effects of contemporary ART drugs were investigated using in vitro and in vivo models of HIV-1 brain infection. RESULTS: The EC(50) values for specific ART drugs in HIV-infected human microglia were significantly higher compared to bone marrow-derived macrophages and peripheral blood mononuclear cells. Intracellular ART drug concentrations in microglia were significantly lower than in human lymphocytes. In vivo brain concentrations of ART drugs in mice were 10 to 100-fold less in brain tissues compared with plasma and liver levels. In brain tissues from untreated HIV-infected BLT mice, HIV-encoded RNA, DNA and p24 were present in human leukocytes while ART eradicated viral RNA and DNA in both brain and plasma. Interruption of ART resulted in detectable viral RNA and DNA and increased human CD68 expression in brains of HIV-infected BLT mice. In aviremic HIV/AIDS patients receiving effective ART, brain tissues that were collected within hours of last ART dosing showed HIV-encoded RNA and DNA with associated neuroinflammatory responses. CONCLUSIONS: ART drugs show variable concentrations and efficacies in brain myeloid cells and tissues in drug-specific manner. Despite low drug concentrations in brain, experimental ART suppressed HIV-1 infection in brain although HIV/AIDS patients receiving effective ART had detectable HIV-1 in brain. These findings suggest that viral suppression in brain is feasible but new approaches to enhancing ART efficacy and concentrations in brain are required for sustained HIV-1 eradication from brain. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12977-017-0370-5) contains supplementary material, which is available to authorized users. BioMed Central 2017-10-16 /pmc/articles/PMC5644262/ /pubmed/29037245 http://dx.doi.org/10.1186/s12977-017-0370-5 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Asahchop, Eugene L. Meziane, Oussama Mamik, Manmeet K. Chan, Wing F. Branton, William G. Resch, Lothar Gill, M. John Haddad, Elie Guimond, Jean V. Wainberg, Mark A. Baker, Glen B. Cohen, Eric A. Power, Christopher Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain |
title | Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain |
title_full | Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain |
title_fullStr | Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain |
title_full_unstemmed | Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain |
title_short | Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain |
title_sort | reduced antiretroviral drug efficacy and concentration in hiv-infected microglia contributes to viral persistence in brain |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644262/ https://www.ncbi.nlm.nih.gov/pubmed/29037245 http://dx.doi.org/10.1186/s12977-017-0370-5 |
work_keys_str_mv | AT asahchopeugenel reducedantiretroviraldrugefficacyandconcentrationinhivinfectedmicrogliacontributestoviralpersistenceinbrain AT mezianeoussama reducedantiretroviraldrugefficacyandconcentrationinhivinfectedmicrogliacontributestoviralpersistenceinbrain AT mamikmanmeetk reducedantiretroviraldrugefficacyandconcentrationinhivinfectedmicrogliacontributestoviralpersistenceinbrain AT chanwingf reducedantiretroviraldrugefficacyandconcentrationinhivinfectedmicrogliacontributestoviralpersistenceinbrain AT brantonwilliamg reducedantiretroviraldrugefficacyandconcentrationinhivinfectedmicrogliacontributestoviralpersistenceinbrain AT reschlothar reducedantiretroviraldrugefficacyandconcentrationinhivinfectedmicrogliacontributestoviralpersistenceinbrain AT gillmjohn reducedantiretroviraldrugefficacyandconcentrationinhivinfectedmicrogliacontributestoviralpersistenceinbrain AT haddadelie reducedantiretroviraldrugefficacyandconcentrationinhivinfectedmicrogliacontributestoviralpersistenceinbrain AT guimondjeanv reducedantiretroviraldrugefficacyandconcentrationinhivinfectedmicrogliacontributestoviralpersistenceinbrain AT wainbergmarka reducedantiretroviraldrugefficacyandconcentrationinhivinfectedmicrogliacontributestoviralpersistenceinbrain AT bakerglenb reducedantiretroviraldrugefficacyandconcentrationinhivinfectedmicrogliacontributestoviralpersistenceinbrain AT cohenerica reducedantiretroviraldrugefficacyandconcentrationinhivinfectedmicrogliacontributestoviralpersistenceinbrain AT powerchristopher reducedantiretroviraldrugefficacyandconcentrationinhivinfectedmicrogliacontributestoviralpersistenceinbrain |